-

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

The Company to host an earnings conference call via webcast

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2025, on Thursday, March 13, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period.

Conference Call and Webcast Details

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, March 13, 2025, at 10:30AM ET.

The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.

***Participant Dial-In Details***

Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name.

USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Canada - Toll-Free (800) 715-9871

***Webcast Details***

Attendee URL:
https://events.q4inc.com/attendee/849565157

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Contacts

Investor Relations
investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Relations
investors@ipatherapeutics.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session....

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequenc...

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease. The work demonstrates MindWalk’s ability to discriminate with structural precision between toxi...
Back to Newsroom